Treatments for behavioural disorders in neurodegenerative diseases: Drug development strategies

Nature Reviews Drug Discovery

Volumn 5, Issue 1, 2006, Pages 64-74

  Cummings, Jeffrey L ^a   Zhong, Kate ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MediChamp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA SECRETASE; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; FLUORODEOXYGLUCOSE; GALANTAMINE; GAMMA SECRETASE INHIBITOR; IMMUNOMODULATING AGENT; LITHIUM; MEMANTINE; NATURAL PRODUCT; NOOTROPIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TAU PROTEIN; VALPROIC ACID;

ALZHEIMER DISEASE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER MODEL; CORTICOBASAL DEGENERATION; CULTURAL FACTOR; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FRONTOTEMPORAL DEMENTIA; HIGH THROUGHPUT SCREENING; HUMAN; LEWY BODY; LOW DRUG DOSE; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN FOLDING; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RATING SCALE; REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VALIDATION PROCESS; ANIMAL; BEHAVIOR; DRUG DESIGN; PSYCHOLOGICAL ASPECT;

ANIMALS; BEHAVIORAL SYMPTOMS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; NEURODEGENERATIVE DISEASES; PSYCHOTROPIC DRUGS;

EID: 33644864745     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1928     Document Type: Review

References (127)

1. Mega, M. S., Cummings, J. L., Fiorello, T. & Gornbein, J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135 (1996).
2. Aarsland, D., Cummings, J. L. & Larsen, J. P. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry 16, 184-191 (2001).
3. Murman, D. L. et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 25, 1721-1729 (2002).
4. Kaufer, D. I. et al. Assessing neuropsychiatric symptoms in clinical practice: The Neuropsychiatric Inventory Questionnaire (NPI-Q). J. Neuropsychiatry Clin. Neurosci. 11, 145-146 (1999).
5. Shin, I. S., Carter, M., Masterman, D., Fairbanks, I. & Cummings, J. L. Neuropsychiatric symptoms and quality of life in Alzheimer's disease. Am. J. Geriatr. Psychiatry 13, 469-474 (2005).
6. Cummings, J. L. et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314 (1994).
7. Cummings, J. L., Schneider, L., Tariot, P. N., Kershaw, P. R. & Yuan, W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am. J. Psychiatry 161, 532-538 (2004).
8. Cummings, J. L. The neuropsychiatric burden of neurological diseases in the elderly. Int. Psychogeriatr. (in the press).
9. Levy, M. L., Miller, B. L., Cummings, J. L., Fairbanks, L. A. & Craig, A. Alzheimer disease and frontotemporal dementias: Behavioral distinctions. Arch. Neurol. 53, 687-690 (1996).
10. Mckeith, I. G. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124 (1996).
11. Litvan, I., Mega, M. S., Cummings, J. L. & Fairbanks, L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 47, 1184-1189 (1996).
12. Litvan, I., Cummings, J. L. & Mega, M. Neuropsychiatric features of corticobasal degeneration. J. Neurol. Neurosurg. Psychiatry 65, 717-721 (1998).
13. Sink, K. M., Holden, K. F. & Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 293, 596-608 (2005).
14. Cummings, J. L. Drug therapy: Alzheimer's disease. N. Engl. J. Med. 351, 56-67 (2004).
15. Cummings, J. L. Towards a molecular neuropsychiatry of neurodegenerative diseases. Ann. Neurol. 54, 147-154 (2003).
16. Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
17. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev. Neurosci. 4, 49-60 (2003).
18. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
19. Cummings, J. L., Vinters, H. V., Cole, G. M. & Khachaturian, Z. S. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51, S2-S17 (1998).
20. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
21. Hartzler, A. W. et al. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: A mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol. Aging 23, 855-859 (2002).
22. Hong, M. et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914-1917 (1998).
23. Hirono, N., Mega, M. S., Dinov, I. D., Mishkin, F. & Cummings, J. L. Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Arch. Neurol. 57, 861-866 (2000).
24. Lanctot, K. L. et al. Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch. Neurol. 61, 1731-1737 (2004).
25. Kotrla, K. J., Chacko, R. C., Harper, R. G., Jhingran, S. & Doody, R. SPECT findings on psychosis in Alzheimer's disease. Am. J. Psychiatry 152, 1470-1475 (1995).
26. Mega, M. et al. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 69, 167-171 (2000).
27. Ponton, M. O. et al. Psychometric and SPECT studies in Alzheimer's disease with and without delusions. Neuropsychiatry Neuropsychol. Behav. Neurol. 8, 264-270 (1995).
28. Staff, R. T. et al. Delusions in Alzheimer's disease: SPET evidence of right hemispheric dysfunction. Cortex 35, 549-560 (1999).
29. Starkstein, S. E., Vazquez, S. & Petracca, G. A SPECT study of delusions in Alzheimer's disease. Neurology 44, 2055-2059 (1994).
30. Grady, C. L. et al. Subgroups in dementia of the Alzheimer type identified using positron emission tomography. J. Neuropsychiatry Clin. Neurosci. 2, 373-384 (1990).
31. Mentis, M. J. et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: A positron emission tomography study in Alzheimer disease. Biol. Psychiatry 38, 438-449 (1995).
32. Sweet, R. A. et al. Psychosis in Alzheimer disease: Postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol. Aging 23, 547-553 (2002).
33. Engelborghs, S., Vloeberghs, E., Maertens, K., Marescau, B. & De Deyn, P. P. Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1080 (2004).
34. Farber, N. B. et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch. Gen. Psychiatry 57, 1165-1173 (2000).
35. Tekin, S. et al. Orbitofrontal and anterior cingulate cortex: neurofibrillary tangle burden is associated with agitation in Alzheimer's disease. Ann. Neurol. 49, 355-361 (2001).
36. Marshall, G. A., Fairbanks, L., Tekin, S. et al. Neuropathologic correlates of apathy in Alzheimer's disease. Ann. Neurol. 64, A136-A137 (2005).
37. 2 binding in the cortex. Neurology 57, 805-811 (2001).
38. Minger, S. L. et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55, 1460-1467 (2000).
39. Assal, F. et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch. Neurol. 61, 1249-1253 (2004).
40. 2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum. Mol. Genet. 7, 1507-1509 (1998).
41. 2A receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol. Psychiatry 50, 472-475 (2001).
42. Devanand, D. et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am. J. Psychiatry 155, 1512-1520 (1998).
43. De Deyn, P. P. et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53, 946-955 (1999).
44. Brodaty, H. et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J. Clin. Psychiatry 64, 134-143 (2003).
45. Katz, I. R. et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J. Clin. Psychiatry 60, 107-115 (1999).
46. Street, J. S. et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. A double-blind, randomized, placebo-controlled trial. Arch. Gen. Psychiatry 57, 968-976 (2000).
47. Zhong, K. et al. Quetiapine in the treatment of agitation in patients with Alzheimer's disease. Int. Psychogeriatrics Stockholm, Sweden, 20-24 September, 325-326 (2005).
48. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757-763 (1999).
49. Walker, Z. et al. Olanzapine in dementia with Lewy bodies: A clinical study. Int. J. Geriatr. Psychiatry 14, 459-466 (1999).
50. Targum, S. D. & Abbott, J. L. Efficacy of quetiapine in Parkinson's patients with psychosis. J. Clin. Psychophormacol. 20, 54-60 (2000).
51. Parsa, M. A. & Bastani, B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 10, 216-219 (1998).
52. Lyketsos, C. G. et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction, the DIADS. Arch. Gen. Psychiatry 60, 737-746 (2003).
53. Ceravolo, R. et al. Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology 55, 1216-1218 (2000).
54. Hauser, R. & Zesiewicz, T A. Sertraline for the treatment of depression in Parkinson's disease. Mov. Disord. 12, 756-759 (1997).
55. Tariot, P. N. et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am. J. Psychiatry 155, 54-61 (1998).
56. Porsteinsson, A. P., Tariot, P. N., Erb, R. & Gaile, S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am. J. Geriatr. Psychiatry 5, 344-351 (1997).
57. Porsteinsson, A. P. et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 11, 434-440 (2003).
58. Ondo, W. G., Tintner, R., Voung, K. D., Lai, D. & Ringholz, G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20, 958-963 (2005).
59. Ballard, C. et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ 330, 874 (2005).
60. Zhong, K. et al. Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: A randomized, double-blind trial. Am. Assoc. Geriatric Psychiatry San Diego, California, USA, 5-6 March (2005).
61. Caligiuri, M. P., Rockwell, E. & Jeste, D. V. Extra-pyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication. Am. J. Geriatr. Psychiatry 6, 75-82 (1998).
62. Cummings, J. L. Cholinesterase inhibitors: A new class of psychotropic agents. Am. J. Psychiatry 157, 4-15 (2000).
63. Trinh, N. H., Hoblyn, J., Mohanty S. & Yaffe, K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA 289, 210-216 (2003).
64. Feldman, H. et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57, 613-620 (2001).
65. Gauthier, S. et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr. 14, 389-404 (2002).
66. Tariot, P. N. et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54, 2269-2276 (2000).
67. Rosler, M., Retz, W., Retz-Junginger, P. & Dennler, H. J. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav. Neurol. 11, 211-216 (1998).
68. Holmes, C. et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63, 214-219 (2004).
69. Emre, M. et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518 (2004).
70. Minett, T. S. et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry 18, 988-993 (2003).
71. Mckeith, I. et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356, 2031-2036 (2000).
72. Tariot, P. N. et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J. Am. Geriatr. Soc. 49, 1590-1599 (2001).
73. Cummings, J. L. Dementia: Clinical evaluation. Annu. Conf. Acad. Molecular Imaging Orlando, Florida, USA, 18-23 March, Abstract number 84 (2005).
74. Price, D. L., Sisodia, S. S. & Borchelt, D. R. Genetic neurodegenerative diseases: The human illness and transgenic models. Science 282, 1079-1083 (1998).
75. Van Dam, D. & De Deyn, P. P. Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model. Eur. Neuropsychopharmacol. 8 August 2005 [epub ahead of print].
76. Jackson, G. et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519 (2002).
77. Sano, M. et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336, 1216-1222 (1997).
78. Laks, J. et al. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq. Neuropsiquiatr. 59, 859-864 (2001).
79. Laughren, T. A regul atory perspective on psychiatric syndromes in Alzheimer disease. Am. J. Geriatr. Psychiatry 9, 340-345 (2001).
80. Cummings, J. L. & Jeste, D. V. Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: Definitional and regulatory aspects. Econ. Neurosci. 5, 36-40 (2003).
81. Jeste, D. V. & Finkel, S. I. Psychosis of Alzheimer's disease and related dementias. Am. J. Geriatr. Psychiatry 8, 29-34 (2000).
82. Olin, J. T. et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 125-128 (2002).
83. Cummings, J. L. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48, S10-S16 (1997).
84. Wood, S. et al. The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am. J. Geriatr. Psychiatry 8, 75-83 (2000).
85. Mega, M. S., Masterman, D. M., O'connor, S. M., Barclay, T. R. & Cummings, J. L. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's disease. Arch. Neurol. 56, 1388-1393 (1999).
86. Reisberg, B. et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 48, 9-15 (1987).
87. Overall, J. E. & Gorham, D. R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10, 799-812 (1962).
88. Cohen-Mansfield, J., Marx, M. S. & Rosenthal, A. S. A description of agitation in a nursing home. J. Gerontology 44, M77-M84 (1989).
89. Alexopoulos, G. S. et al. Cornell scale for depression in dementia. Biol. Psychiatry 23, 271-284 (1988).
90. Hamilton, M. Hamilton Depression Rating Scale. J. Neurol. Neurosurg. Psychiatry 23, 56-62 (1960).
91. Lindenmayer, J. P. et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr. Res. 68, 331-337 (2004).
92. Friedman, L. et al. Disruptive behavior and actigraphic measures in home-dwelling patients with Alzheimer's disease: Preliminary report. J. Geriatr. Psychiatry Neurol. 10, 58-62 (1997).
93. Schneider, L. S. et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis. Assoc. Disord. 11, S22-S32 (1997).
94. Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141, 1356-1364 (1984).
95. Mohs, R. C. et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study Alzheimer Dis. Assoc. Disord. 11 (Suppl. 2), S13-S21 (1997).
96. Swanberg, M. M., Tractenberg, R. E., Mohs, R., Thai, L. J. & Cummings, J. L. Executive dysfunction in Alzheimer disease. Arch. Neurol. 61, 556-560 (2004).
97. Galasko, D. et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 11, S33-S39 (1997).
98. Boyle, P. A. et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am. J. Geriatr. Psychiatry 11, 214-221 (2003).
99. Tekin, S., Fairbanks, L. A., O'connor, S., Rosenberg, S. & Cummings, J. L. Activities of daily living in Alzheimer's disease: Neuropsychiatric, cognitive, and medical illness influences. Am. J. Geriatr. Psychiatry 9, 81-86 (2001).
100. Chen, S. T., Sultzer, D. L., Hinkin, C. H., Mahler, M. E. & Cummings, J. L. Executive dysfunction in Alzheimer's disease: Association with neuropsychiatric symptoms and functional impairment. J. Neuropsychiatry Clin. Neurosci. 10, 426-432 (1998).
101. Wimo, A., Winblad, B., Stoffter, A., Wirth, Y. & Mobius, H. J. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21, 327-340 (2003).
102. Levy, M. L. et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am. J. Psychiatry 153, 1438-1443 (1996).
103. Devanand, D. P. et al. The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch. Gen. Psychiatry 54, 257-263 (1997).
104. Teri, L. et al. Treatment of agitation in Alzheimer's disease: A randomized placebo controlled clinical trial. Neurology 55, 1271-1278 (2000).
105. Cohen-Mansfield, J. Turnover among nursing home staff. A review. Nurs. Manage. 28, 59-62, 64 (1997).
106. Mega, M. S. et al. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 12, 209-218 (2000).
107. Mega, M. et al. Metabolic patterns associated with the clinical response to galantamine therapy. Arch. Neurol. 62, 721-728 (2005).
108. Clark, W. S., Street, J. S., Feldman, P. D. & Breier, A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J. Clin. Psychiatry 62, 34-40 (2001).
109. Fuh, J. L. et al. A transcultural study of agitation in dementia. J. Geriatr. Psychiatry Neurol. 15, 171-174 (2002).
110. Fuh, J. L., Liu, C. K., Mega, M. S., Wang, S. J. & Cummings, J. L. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int. Psychogeriatr. 13, 121-128 (2001).
111. Ballard, C. G. et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am. J. Psychiatry 161, 843-849 (2004).
112. Ballard, C. G. et al. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: Persistence and new cases over 1 year of follow-up. J. Clin. Psychiatry 62, 46-49 (2001).
113. Petersen, R. C. et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985-1992 (2001).
114. Petersen, R. C. et al. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 56, 303-308 (1999).
115. Huang, H. L., Shyu, Y. I., Chen, M. C., Chen, S. T. & Lin, L. C. A pilot study on a home-based caregiver training program for improving caregiver self-efficacy and decreasing the behavioral problems of elders with dementia in Taiwan. Int. J. Geriatr. Psychiatry 18, 337-345 (2003).
116. Lyketsos, C. G. et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 288, 1475-1483 (2002).
117. Lopez, O. L. et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 2. Arch. Neurol. 60, 1394-1399 (2003).
118. Copeland, M. P. et al. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 17, 1-8 (2003).
119. Malberg, J. E., Eisch, A. J., Nestler, E. J. & Duman, R. S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104-9110 (2000).
120. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809 (2003).
121. Sweet, R. A. et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int. Psychogeriatr. 13, 401-409 (2001).
122. Sukonick, D. L. et al. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch. Neurol. 58, 1425-1428 (2001).
123. De Deyn, P., Jeste, D. V., Swanink, R., Kostic, D. & Breder, C. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study. J. Clin. Psychopharmacol. 25, 463-467 (2005).
124. Porsteinsson, A. P. et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriatr. Psychiatry 9, 58-66 (2001).
125. Erkinjuntti, T. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 359, 1283-1290 (2002).
126. Tariot, P. N. et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324 (2004).
127. Meehan, K. et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26, 494-504 (2002).